View Cart  

Study: Novartis’ Fingolimod Superior to Avonex

A A
Novartis reported positive Phase III clinical trial data on its investigational multiple sclerosis (MS) treatment fingolimod, an oral medication shown to have superior efficacy in treating relapsing-remitting MS compared with Biogen Idec’s Avonex.

 

The TRANSFORMS study — a 1,292-patient, double-blind, head-to-head trial — tested two doses of the product against Avonex (interferon beta 1a) in subjects with relapsing-remitting MS.

 

The 0.5-mg dose of fingolimod showed a statistically significant 52 percent greater reduction in the risk of disease relapse after one year of treatment compared with Avonex and a 38 percent greater reduction in risk for the same endpoint for the 1.25-mg dose, Novartis said.